دورية
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
| العنوان: | Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma |
|---|---|
| المؤلفون: | Rifkin, Robert M., Bell, Jill A., DasMahapatra, Pronabesh, Hoole, Michael, Lowe, Maria, Curran, Chris, Campbell, Scott, Hou, Peijie, Romanus, Dorothy |
| المصدر: | PharmacoEconomics - Open; 20240101, Issue: Preprints p1-11, 11p |
| مستخلص: | Objectives: This observational study identified attributes of patient-reported satisfaction with therapy for multiple myeloma (MM), described the treatment-related time burden and indirect costs, and investigated the effect of administration route (oral vs. injectable) on these outcomes among patients with newly diagnosed MM (NDMM) and among caregivers. Methods: Patients residing in the USA with a self-reported diagnosis of NDMM were recruited from PatientsLikeMe, MyelomaCrowd, and Facebook (16 December 2016 and 6 July 2017) to complete an electronic survey including questions on treatment experience, economic burden, and standardized patient-reported outcome measures, including the Treatment Satisfaction Questionnaire for Medication with three domains (global satisfaction, effectiveness, and convenience) and the Work Productivity and Activity Impairment Questionnaire. Univariate and multivariate analyses identified predictors of patient-perceived treatment satisfaction. Results: Among 188 patients, worse Eastern Cooperative Oncology Group performance status (ECOG PS) was correlated with lower patient-perceived effectiveness and convenience of their current treatment. White race and oral administration route were independently correlated with higher patient-perceived convenience of treatment. Injectable therapy use was associated with a trend towards increased activity impairment (43 vs. 34%; p?=?0.05) and significantly higher time burden of treatment administration, with threefold higher adjusted indirect costs of MM therapy compared with solely orally administered therapies (monthly mean $US482 vs. 153; 2016 values; p?<?0.0001). Conclusions: Factors associated with patient-perceived satisfaction with NDMM treatment—ECOG PS, race, administration route—warrant increased attention in shared treatment decision making to help identify patient needs and improve the patient’s treatment experience. The use of orally administered therapies could improve patients’ activity impairment and reduce the time burden associated with therapy. |
| قاعدة البيانات: | Supplemental Index |
Full Text Finder | تدمد: | 25094262 25094254 |
|---|---|
| DOI: | 10.1007/s41669-019-00184-9 |